Merz Pharma

Hyalex Orthopaedics Appoints Thomas Vail, M.D., as Chief Medical Officer and Names Adam Gridley to Board of Directors

Retrieved on: 
月曜日, 4月 15, 2024
Education, Sale, University, Hip, Regenerative medicine, Abstract, Merz Pharma, Cartilage, Research, Trustee, ARM, Orthopedic surgery, IPO, Journal, Therapy, UCSF, Joint, Patient, Health, Biotechnology, Global health, Pharmaceutical industry

LEXINGTON, Mich., April 15, 2024 /PRNewswire/ -- Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, today announced the appointment of Thomas "Tad" Vail, M.D., as chief medical officer. Dr. Vail is internationally recognized as a specialist in total and partial joint replacement and surgical treatment of hip and knee conditions, having most recently served as the Michael and Antoinette Pappas endowed chair and James L. Young professor of orthopaedic surgery at the University of California, San Francisco (UCSF). Additionally, Hyalex announced the appointment of Adam Gridley, the chief executive officer of Allay Therapeutics, to the company's board of directors. These two appointments significantly augment the scientific and operational expertise of the Hyalex team at a time when the company is bringing its novel HYALEX Cartilage platform into first-in-human clinical trials.

Key Points: 
  • LEXINGTON, Mich., April 15, 2024 /PRNewswire/ -- Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, today announced the appointment of Thomas "Tad" Vail, M.D., as chief medical officer.
  • Additionally, Hyalex announced the appointment of Adam Gridley, the chief executive officer of Allay Therapeutics, to the company's board of directors.
  • "Hyalex is entering an exciting and transformational period for the company, as we advance our novel HYALEX Cartilage platform into the clinic for the first time.
  • "We look forward to the important contributions that both Tad and Adam will make to the success of the company."

ProPharma Announces Changes to Its Executive Leadership Team

Retrieved on: 
木曜日, 4月 11, 2024
Odyssey, ICON PLC, Lead, CMO, Social media, General counsel, Merz Pharma, Shaw, Heart, RCO, PRA Health Sciences, Private practice, Research, GSK, Marketing, CIO, Labcorp, Global marketing, Icon, CPG, Global health, Management

RALEIGH, N.C., April 11, 2024 /PRNewswire/ -- ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners is pleased to announce that it has welcomed Kirk Wroblewski as its new Chief Information Officer (CIO) and Andrew Shaw as General Counsel. In addition, ProPharma has promoted Zosya Popik to Chief Marketing Officer (CMO), previously the Vice President of Global Marketing.

Key Points: 
  • In addition, ProPharma has promoted Zosya Popik to Chief Marketing Officer (CMO), previously the Vice President of Global Marketing.
  • "We are thrilled to welcome Kirk and Andrew to the executive team and to elevate Zosya as our new Chief Marketing Officer," said Mike Stomberg, Chief Executive Officer.
  • "The combined expertise of each of these team members positions ProPharma to transcend in the industry and continue to compete on a global scale."
  • Wroblewski is a highly accomplished, solutions-focused information executive with more than 20 years of experience in healthcare data and analytics.

ProPharma Announces Changes to Its Executive Leadership Team

Retrieved on: 
水曜日, 4月 10, 2024
Odyssey, ICON PLC, Lead, CMO, Social media, General counsel, Merz Pharma, Shaw, Heart, RCO, PRA Health Sciences, Private practice, Research, GSK, Marketing, CIO, Labcorp, Global marketing, Icon, CPG, Global health, Management

RALEIGH, N.C., April 10, 2024 /PRNewswire-PRWeb/ -- ProPharma https://www.propharmagroup.com/, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners https://www.odysseyinvestment.com/ is pleased to announce that it has welcomed Kirk Wroblewski as its new Chief Information Officer (CIO) and Andrew Shaw as General Counsel. In addition, ProPharma has promoted Zosya Popik to Chief Marketing Officer (CMO), previously the Vice President of Global Marketing.

Key Points: 
  • "We're thrilled to welcome Kirk and Andrew to the executive team and to elevate Zosya as our new Chief Marketing Officer," said Mike Stomberg, CEO.
  • "The combined expertise of each of these team members positions ProPharma to transcend in the industry and continue to compete on a global scale."
  • "We are thrilled to welcome Kirk and Andrew to the executive team and to elevate Zosya as our new Chief Marketing Officer," said Mike Stomberg, Chief Executive Officer.
  • "The combined expertise of each of these team members positions ProPharma to transcend in the industry and continue to compete on a global scale."

Planatome Completes Spinout from Parent Company, Bolsters Executive Team with Key New Hires

Retrieved on: 
火曜日, 10月 10, 2023
Patent, Silicon, Hospital, MBA, Veteran, Inflammation, Bachelor of Engineering, Modular Engine Management System, Johnson & Johnson, George Washington University, Robotics, Health, FDA, Trauma, Growth, Merz Pharma, Scar, Surgeon, Instrument, Patient, Pennsylvania State University, Troy University, Dentistry, Management, Engineering

The company also announced today that it has expanded its leadership team with the addition of two key industry executives.

Key Points: 
  • The company also announced today that it has expanded its leadership team with the addition of two key industry executives.
  • Surgeons using our blades have told us they see improved outcomes, setting a new standard of care as a result."
  • Currently in use by surgeons across the country, Planatome blades have proven to be a low-trauma, high-precision surgical tool.
  • To learn more about Planatome and its new hires, follow the company on LinkedIn: Planatome LinkedIn and Keith Jeffcoat and Steve Joachim .

Dermal Fillers Market to Surpass $9.13 Billion by 2028, Market Driven by Medical Tourism & Aesthetic Treatment - Arizton

Retrieved on: 
火曜日, 4月 11, 2023
Collection, Travel, Medical tourism, Galderma, Ageing, Privacy, Cosmeceutical, Patient, Risk, Growth, Merz Pharma, Chin, FDA, Therapy, Filler (linguistics), Human, Pharmaceutical industry, Medical device, European

Download the Free Sample Report: https://www.arizton.com/request-sample/3771

Key Points: 
  • Download the Free Sample Report: https://www.arizton.com/request-sample/3771
    Over the last decade, the global dermal fillers market has witnessed the launch of advanced products and innovative non-invasive procedures.
  • In 2020, TEOXANE signed a distribution agreement with Revance Therapeutics to distribute the US's RHA Collection of dermal fillers.
  • Moreover, medical tourism provides access to a wider range of dermal fillers and related treatments for cost-effectiveness, convenience, and access to quality medical care.
  • Therefore, medical tourism is providing a better opportunity for vendors of dermal fillers in many ways.

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust Litigation

Retrieved on: 
月曜日, 12月 5, 2022
Class Action Lawsuit, Professional Services, Legal, Summons, Court order, Forest Laboratories, Hearing, District court, Teva, Sun Pharma, AB, Merz, Upsher-Smith Laboratories, TPP Nikola Tesla, Generic, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Person, Court, Comment, Partnership, Merz Pharma, Actavis, Laboratory, Tablet, Indian Residential Schools Settlement Agreement, Generic drug, Insurance, Life insurance, Memantine

The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).

Key Points: 
  • The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).
  • The settlement with Teva includes the AB-rated generic versions of Namenda IR 5 or 10 mg tablets.
  • If you are a member of one or both classes, you may comment on or object to the proposed settlements.
  • You must object to the settlements by February 3, 2023, or request to be excluded from the class by February 3, 2023.

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust Litigation

Retrieved on: 
月曜日, 12月 5, 2022
Summons, Court order, Settlement, Court, Forest Laboratories, Hearing, District court, Teva, Plaintiff, Sun Pharma, AB, Alzheimer's disease, Merz, Upsher-Smith Laboratories, TPP Nikola Tesla, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Person, Comment, Partnership, Merz Pharma, Actavis, Laboratory, Tablet, Tobacco Master Settlement Agreement, Inwood Laboratories, Inc. v. Ives Laboratories, Inc., Wockhardt, Generic drug, Insurance, Life insurance, Memantine

The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).

Key Points: 
  • The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).
  • The settlement with Teva includes the AB-rated generic versions of Namenda IR 5 or 10 mg tablets.
  • If you are a member of one or both classes, you may comment on or object to the proposed settlements.
  • You must object to the settlements by February 3, 2023,or request to be excluded from the class by February 3, 2023.

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust Litigation

Retrieved on: 
木曜日, 12月 1, 2022
Class Action Lawsuit, Professional Services, Legal, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Upsher-Smith Laboratories, Comment, Merz Pharma, Tablet, Court order, Generic, AB, Indian Residential Schools Settlement Agreement, Merz, Actavis, Sun Pharma, TPP Nikola Tesla, District court, Summons, Teva, Partnership, Court, Laboratory, Person, Forest Laboratories, Hearing, Generic drug, Insurance, Life insurance, Memantine

The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).

Key Points: 
  • The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).
  • The settlement with Teva includes the AB-rated generic versions of Namenda IR 5 or 10 mg tablets.
  • If you are a member of one or both classes, you may comment on or object to the proposed settlements.
  • You must object to the settlements by February 3, 2023, or request to be excluded from the class by February 3, 2023.

$25+ Billion Antifungal Drugs Markets, 2030 by Drug Class, Infection Type, Therapeutic Indications, Dosage Forms - ResearchAndMarkets.com

Retrieved on: 
木曜日, 9月 8, 2022
Health, General Health, Conditional sentence, Candidiasis, Polyene, Form, Dermatophytosis, CDC, Disease, Death, Incidence, Infection, Gilead Sciences, Skin, Merz Pharma, Bloodstream infections, Pfizer, Mycosis, Center, Azole, Prevalence, CAGR, Population, Immunodeficiency, Centers for Disease Control and Prevention, Bayer, Echinocandin, Johnson & Johnson, Tuberculosis, Abbott Laboratories, Diabetes, Blastomycosis, Growth, Drug development, Region, Environment, Patient, Pharmaceutical industry, Fine chemical, Aspergillosis

The "Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The anti-fungal drugs market was valued at $16,572.1 million in 2020, and is estimated to reach $25,045.20 million by 2030, growing at a CAGR of 3.9% from 2021 to 2030.
  • Moreover, the key players Pfizer Inc., Abbott Laboratories, and Bayer Ag provide numerous anti-fungal drugs that contribute toward the market growth.
  • The antifungal drugs market is segmented on the basis of drug type, therapeutic indication, infection type, and region.

Insights on the Cosmetic Surgery Global Market to 2027 - Size, Trends & Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
月曜日, 7月 25, 2022
Surgery, Health, Other Health, SWOT, Gender, Cleveland Clinic, Industry, Johnson & Johnson, Procedure, Research, Allergan, Inc., Merz Pharma, Review, Long Island Plastic Surgical Group, P.C, Bausch Health, Galderma, Porter's five forces analysis, Genesis, Retail

The "Global Cosmetic Surgery Market Size, Trends & Growth Opportunity, By Procedure, By End-User, By Gender, and Forecast till 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cosmetic Surgery Market Size, Trends & Growth Opportunity, By Procedure, By End-User, By Gender, and Forecast till 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cosmetic Surgery Market research study includes a forecast, share, size, and dynamics analysis.
  • The Global Cosmetic Surgery Market has been evaluated for the forecast period using Porter's Five Force Model for the review period of 2020 to 2027.
  • The study examines Global Cosmetic Surgery Market drivers and restraints, as well as their impact on demand, throughout the forecast period.